Stuart Rowling - Paxman AB Head Sales
| PXMBF Stock | USD 3.50 0.00 0.00% |
Insider
Stuart Rowling is Head Sales of Paxman AB
| Age | 41 |
| Web | https://paxmanscalpcooling.com |
Paxman AB Management Efficiency
The company has return on total asset (ROA) of (0.0412) % which means that it has lost $0.0412 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0254) %, meaning that it generated substantial loss on money invested by shareholders. Paxman AB's management efficiency ratios could be used to measure how well Paxman AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Artur Aira | Cellink AB | 56 | |
| Dennis Urbaniak | Orexo AB ADR | 54 | |
| Angelika Florvaag | Hofseth BioCare ASA | N/A | |
| Karin Danielsson | BICO Group AB | 41 | |
| Sacha Dopheide | Lumos Diagnostics Holdings | N/A | |
| Hector Martinez | Cellink AB | 38 | |
| Erica Bell | Cellink AB | 50 | |
| Lotta Bus | Cellink AB | 53 | |
| Lotta Bus | BICO Group AB | 53 | |
| Santiago Luengo | VITA 34 AG | N/A | |
| Shakeel Osman | Venus Medtech | N/A | |
| BBus CA | Lumos Diagnostics Holdings | 49 | |
| Kathy McGee | Avita Medical | 58 | |
| Christopher Richardson | Venus Medtech | 62 | |
| HouSen MEng | Venus Medtech | 50 | |
| Dirk Plaga | VITA 34 AG | 58 | |
| Karl Slotsvik | Hofseth BioCare ASA | N/A | |
| Hector Martinez | BICO Group AB | 38 | |
| James Berger | Hofseth BioCare ASA | N/A | |
| Andrew Quick | Avita Medical | 53 | |
| Jennifer Christiansen | Lumos Diagnostics Holdings | N/A | |
Management Performance
| Return On Equity | -0.0254 | |||
| Return On Asset | -0.0412 |
Paxman AB Leadership Team
Elected by the shareholders, the Paxman AB's board of directors comprises two types of representatives: Paxman AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Paxman. The board's role is to monitor Paxman AB's management team and ensure that shareholders' interests are well served. Paxman AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Paxman AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Burke, Head Operations | ||
| Emma Thornhill, Head Fin | ||
| Emelie Gustafsson, Chief Officer | ||
| Claire Paxman, Director Initiatives | ||
| Anna Parker, Head Sales | ||
| Liza Hirst, EA HR | ||
| Stuart Rowling, Head Sales | ||
| Richard Paxman, CEO Director | ||
| Susy Brown, Head Marketing | ||
| Alexandra Sheldrake, Head Affairs |
Paxman Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Paxman AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0254 | |||
| Return On Asset | -0.0412 | |||
| Profit Margin | (0.02) % | |||
| Current Valuation | 76.35 M | |||
| Shares Outstanding | 19.01 M | |||
| Shares Owned By Insiders | 64.44 % | |||
| Shares Owned By Institutions | 7.74 % | |||
| Price To Book | 22.79 X | |||
| Price To Sales | 13.45 X | |||
| Revenue | 96.2 M |
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Paxman Pink Sheet
Paxman AB financial ratios help investors to determine whether Paxman Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Paxman with respect to the benefits of owning Paxman AB security.